95 related articles for article (PubMed ID: 11129985)
1. 17 alpha androstenediol inhibition of breast tumor cell proliferation in estrogen receptor-positive and -negative cell lines.
Huynh PN; Carter WH; Loria RM
Cancer Detect Prev; 2000; 24(5):435-44. PubMed ID: 11129985
[TBL] [Abstract][Full Text] [Related]
2. 17α-androstenediol-mediated oncophagy of tumor cells by different mechanisms is determined by the target tumor.
Loria RM; Graf MR
Ann N Y Acad Sci; 2012 Jul; 1262():127-33. PubMed ID: 22823444
[TBL] [Abstract][Full Text] [Related]
3. Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha.
Maggiolini M; Donzé O; Jeannin E; Andò S; Picard D
Cancer Res; 1999 Oct; 59(19):4864-9. PubMed ID: 10519397
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
5. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells.
Liu ZJ; Zhu BT
J Steroid Biochem Mol Biol; 2004 Mar; 88(3):265-75. PubMed ID: 15120420
[TBL] [Abstract][Full Text] [Related]
6. Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells.
Mueck AO; Seeger H; Wallwiener D
Menopause; 2003; 10(4):332-6. PubMed ID: 12851516
[TBL] [Abstract][Full Text] [Related]
7. Delta(9)-tetrahydrocannabinol inhibits 17beta-estradiol-induced proliferation and fails to activate androgen and estrogen receptors in MCF7 human breast cancer cells.
von Bueren AO; Schlumpf M; Lichtensteiger W
Anticancer Res; 2008; 28(1A):85-9. PubMed ID: 18383828
[TBL] [Abstract][Full Text] [Related]
8. [The inhibiting effect of genistein on the growth of human breast cancer cells in vitro].
He FJ; Wang J; Niu JZ; Wang JF
Zhongguo Zhong Yao Za Zhi; 2002 Dec; 27(12):936-9. PubMed ID: 12776537
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens.
Coradini D; Pellizzaro C; Speranza A; Daidone MG
Cell Mol Life Sci; 2004 Jan; 61(1):76-82. PubMed ID: 14704855
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of endometrial carcinoma cell growth using antisense estrogen receptor oligodeoxyribonucleotides.
Taylor AH; al-Azzawi F; Pringle JH; Bell SC
Anticancer Res; 2002; 22(6C):3993-4003. PubMed ID: 12553024
[TBL] [Abstract][Full Text] [Related]
11. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
[TBL] [Abstract][Full Text] [Related]
12. The proliferative effects of 5-androstene-3 beta,17 beta-diol and 5 alpha-dihydrotestosterone on cell cycle analysis and cell proliferation in MCF7, T47D and MDAMB231 breast cancer cell lines.
Aspinall SR; Stamp S; Davison A; Shenton BK; Lennard TW
J Steroid Biochem Mol Biol; 2004 Jan; 88(1):37-51. PubMed ID: 15026082
[TBL] [Abstract][Full Text] [Related]
13. Dehydroepiandrosterone inhibits the proliferation and induces the death of HPV-positive and HPV-negative cervical cancer cells through an androgen- and estrogen-receptor independent mechanism.
Girón RA; Montaño LF; Escobar ML; López-Marure R
FEBS J; 2009 Oct; 276(19):5598-609. PubMed ID: 19702826
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
[TBL] [Abstract][Full Text] [Related]
15. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
16. Retinoic acid inhibition of human breast carcinoma proliferation is accompanied by inhibition of the synthesis of a Mr 39,000 protein.
Fontana JA; Miranda D; Mezu AB
Cancer Res; 1990 Apr; 50(7):1977-82. PubMed ID: 2317786
[TBL] [Abstract][Full Text] [Related]
17. Tracking the elusive antiestrogenic effect of melatonin: a new methodological approach.
Girgert R; Bartsch C; Hill SM; Kreienberg R; Hanf V
Neuro Endocrinol Lett; 2003 Dec; 24(6):440-4. PubMed ID: 15073572
[TBL] [Abstract][Full Text] [Related]
18. Oestrogen causes G2/M arrest and apoptosis in breast cancer cells MDA-MB-231.
Nomoto S; Arao Y; Horiguchi H; Ikeda K; Kayama F
Oncol Rep; 2002; 9(4):773-6. PubMed ID: 12066207
[TBL] [Abstract][Full Text] [Related]
19. The anti-tumor effects of androstene steroids exhibit a strict structure-activity relationship dependent upon the orientation of the hydroxyl group on carbon-17.
Graf MR; Jia W; Lewbart ML; Loria RM
Chem Biol Drug Des; 2009 Dec; 74(6):625-9. PubMed ID: 19824892
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer.
Kalli KR; Bradley SV; Fuchshuber S; Conover CA
Gynecol Oncol; 2004 Sep; 94(3):705-12. PubMed ID: 15350362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
